The p53 tumour suppressor protein plays a central role in the maintenance of genomic integrity. Mutations of the p53 gene are found in a number of canine cancers and many contribute to tumour formation. Here we describe isolation and expression of the complete wild type canine p53 cDNA. The encoded full length canine p53 protein displays strong sequence homology with p53 proteins from other higher vertebrates. Canine p53 protein produced in vitro was shown to recognize and bind to p53-speci®c DNA targets derived from the p21 and GADD45 promoters and to a consensus p53 binding site. We also show that canine p53 associates with oligonucleotides representing damaged DNA sites and undergoes proteolytic cleavage similar to that described for murine and human p53 proteins. Finally, we show that the canine p53 protein is able to transcriptionally activate a p53-dependent reporter gene in vivo. The results suggest that canine p53 is similar both in structure and function to human p53 and that canine cancer may provide a useful clinical model in the search for eective anti-cancer therapies based on p53.
Introduction
Inactivation of the p53 tumour suppressor gene by point mutation and translocation events has been associated with a large number of human neoplasms (for a recent review see Hainaut et al., 1997) . Recently similar mutations within the canine p53 gene have been identi®ed in a small number of canine cancer types including: thyroid carcinoma (Devilee et al., 1994) , oral papilloma (Mayr et al., 1994) , mammary tumours (Van Leeuwen et al., 1996) , osteosarcoma (Van Leeuwen et al., 1997) , circumanal gland adenoma (Mayr et al., 1997) and lymphoma (Veldhoen et al., 1998) . Overexpression of the canine p53 protein was also observed in tumours of epithelial, mesenchymal and round cell origins (Sagartz et al., 1996; Gamblin et al., 1997; Wolf et al., 1997) . The vast clinical knowledge concerning the identi®cation and treatment of canine cancers and the apparent similarity of p53 inactivation in the tumours of some cancer patients identi®es canine p53 as a potential target for anti-cancer therapy in the dog.
Wild type p53 protein has been shown to play a central role in the regulation of cell growth and in the maintenance of genomic integrity (reviewed in Ko and Prives, 1996; Levine, 1997) . In order to assess the contribution of the p53 protein towards the regulation of cell growth and suppression of tumour formation within the dog, a detailed analysis of the structure and functions of the wild type canine p53 protein must be undertaken. However, the sequence of the full length canine p53 protein is not known. Using reverse transcriptase PCR, we isolated cDNA encoding the full length canine p53 protein. The potential for canine p53 protein to recognise and bind speci®c DNA targets in vitro and transactivate a p53-dependent gene in vivo was assessed. In addition, the ability of canine p53 protein to bind sites of DNA damage and undergo DNAdependent proteolytic cleavage was determined. The results show that canine p53 is similar in structure and function to human and murine p53 proteins. Given the similarities between human and canine p53 we suggest that the canine patient represents a useful clinical model for development of anti-cancer therapy in general.
Results

Isolation of the canine p53 cDNA
The isolation of canine p53 cDNA was carried out using a reverse transcriptase polymerase chain reaction (RT ± PCR) method and a combination of degenerate and canine p53-speci®c primers. Initially, cDNA encompassing the 5' and 3' halves of the canine p53 open reading frame were ampli®ed from total RNA isolated from the peripheral blood leukocytes of a healthy dog. Primer pairs 5'up/cp53dn and cp53up/3'dn (Table 1) were used in the RT ± PCR and the ampli®ed cDNAs were cloned and sequenced. The canine p53 cDNA sequence information obtained was then used to design a second primer pair (NTup and CTdn) speci®c for the initiation and termination sites of the canine p53 open reading frame. RT ± PCR ampli®cation using these primers resulted in the isolation of a 1174 base pair cDNA product encoding the complete 1146 base pair open reading frame of canine p53 (Figure 1 ). The cDNA sequence encoding amino acids 25 ± 300 is identical to that previously reported (Kraegel et al., 1995) .
The predicted canine p53 protein is 381 amino acids in length and displays strong sequence homology with p53 proteins identi®ed in other vertebrate species (Figure 2) . In the sequences shown in Figure 2 , the percentage of identical amino acid positions compared with the canine p53 sequence ranges from 72.3% for murine p53 to 86.3% for feline p53 protein. DNA and protein sequence alignment suggests that the dierence in length between canine and human p53 proteins may be due to deletion within the proline rich region of canine p53 (amino acid residues 61 ± 79) that occurred during evolution (Figure 2) . However, identi®cation of the precise location of the deletion event is not possible due to the highly repetitive nature of the DNA sequence within this region of the p53 gene. It is interesting to note that a similar evolutionary loss of amino acid sequence in the proline rich region may have occurred for ovine p53 (Figure 2) .
Expression of the canine p53 protein
Canine p53 protein was expressed in vitro in rabbit reticulocyte lysate and labelled with 35 S-methionine (Gamble and Milner, 1988; Cook and Milner, 1990) . The protein co-migrates with human p53 protein and displays an apparent molecular mass of 50 kDa ( Figure  3a , arrowhead). The comigration of canine p53 (381 amino acids) and human p53 (393 amino acids) may be due to the eects of local sequence structure within the proline rich region on the overall conformation of the p53 protein. Sequence-dependent eects on p53 protein migration in polyacrylamide gels has been observed previously for polymorphic variants of human p53 (Harris et al., 1986) . Smaller polypeptides produced in the translation of human, murine and canine p53 may be the result of internal initiation or premature termination of translation (Figure 3a) . These truncated products do not interfere with subsequent analysis of the p53 proteins produced in vitro.
Immunoreactivity of the canine p53 protein towards CM-1 rabbit anti-human p53 polyclonal antibody (Sagartz et al., 1996; Gamblin et al., 1997; Wolf et al., 1997) and to the monoclonal PAb240 antibody (Teifke and Lohr, 1996) has been shown in immunohistochemical analyses of canine neoplasms. In order to further de®ne the immunoreactivity of canine p53, we used a panel of monoclonal antibodies in an immunoprecipitation assay (Figure 3b ). The speci®city of each monoclonal antibody is shown in Table 2 . Wild type human p53 protein was immunoprecipitated with DO1, PAb1801, PAb1620 and PAb421. Wild type murine p53 was immunoprecipitated with the antibodies PAb242, PAb248, PAb246, PAb1620, PAb421. Canine p53 protein was recognised by PAb421. Antibody 240 reacted poorly with all three p53 proteins. The PAb240 epitope has been shown to be cryptic within the central core domain of p53 folded in the wild type conformation (Cho et al., 1994) . The results indicate that although the amino acid sequence identity between canine p53 and human and murine p53 proteins is high, the organisation of amino acids on the surface of the p53 molecule may dier considerably between species.
Speci®c DNA binding activity of canine p53 protein Protein sequence alignment shows that the canine p53 protein retains all of the amino acid residues within the Table 1 Oligonucleotides used in the ampli®cation of canine p53 cDNA and the analysis of canine p53 protein Name Sequence
The complete cDNA and predicted protein sequence of canine p53. The sequence information was prepared using the DNA Strider computer program
Characterization of full length canine p53 N Veldhoen and J Milner central core domain that, in human p53, function in the recognition and binding of speci®c DNA targets ( Figure 2 ). The speci®c DNA binding activity of human, murine, and canine p53 proteins was compared in an in vitro binding assay using biotinylated DNA targets bound to streptavidinmagnetic beads (Molinari et al., 1996) . All three p53 proteins bound to DNA targets derived from the p21 and GADD45 promoters and to CON DNA (p53 consensus binding site, Funk et al., 1992) (Figure 4 ). In addition, the order of anity for the dierent target sites was similar for all three p53 proteins; p214GADD454CON (data not shown). Competition between CON DNA free in solution and bound to the magnetic beads showed a threefold reduction in canine p53 protein retained on the beads ( Damaged DNA binding activity of canine p53 protein
Sites of DNA damage are recognised by the p53 protein (Lee et al., 1995; Huang et al., 1996) . This activity has been localized to the C-terminal domain of p53 (Lee et al., 1995) . The strong sequence conservation between canine and human p53 proteins within this region (see Figure 2 ) suggests that canine p53 may also recognise damaged DNA sites. The biotinylated DNA targets included lesion DNA (L-DNA) which contained three cytosine loops (Lee et al., 1995; Molinari et al., 1996) , non lesion DNA (NL-DNA) which provided free blunt ends, and single stranded DNA (ssDNA) (Okorokov et al., 1997) . 
DNA-dependent proteolytic cleavage of canine p53 protein
The p53 protein has been shown to undergo proteolytic cleavage in vitro when bound to damaged DNA (Molinari et al., 1996; Okorokov et al., 1997) . Murine p53 associated with L-DNA, NL-DNA, or ssDNA proteolyses at 378C to produce two major fragments. A fragment of murine p53 called p40, which lacks the N-terminal domain, is retained on the DNA ( Figure 6 , lanes 2, 4 and 6). Proteolytic cleavage of the N-and C-terminal domains produces a p53 core fragment which is released from the DNA ( Figure 6 , lanes 3, 5 and 7). Canine p53 protein also underwent proteolytic cleavage at 378C when associated with L-DNA, NL-DNA, and ssDNA ( Figure  6 ). However, the number of cleavage products for canine p53 is greater than that of the murine protein. Canine p53-dependent transactivation
Wild type human and murine p53 proteins function as potent transcription activators in vivo (Frebourg et al., 1992; Juven et al., 1993) . In order to establish whether canine p53 functions as a trans-acting factor, we performed transient transfection assays in p53 null primary murine embryo ®broblasts (18MEFs) (Donehower et al., 1992) . Canine and murine p53 cDNA under the control of the strong cytomegalovirus (CMV) promoter were cotransfected with a p53-dependent b-galactosidase reporter plasmid containing RGC binding sites for p53 (Frebourg et al., 1992) . Expression of the reporter gene was assessed using an ONPG assay (Rosenthal, 1987) . Transfection of canine or murine p53 cDNA resulted in a similar upregulation of b-galactosidase expression in 18MEF cells when compared with the vector-only control (Figure 7) . The transactivation activity of the p53 protein has previously been localized to the ®rst 43 amino acid residues of the Nterminal domain (Unger et al., 1992) . To determine if the transactivation activity of canine p53 protein was located within the N-terminal domain, we constructed a canine p53 mutant lacking the ®rst 68 amino acids (cp53DN). Cotransfection of the cp53DN mutant failed to activate b-galactosidase expression in the 18MEF cells (Figure 7) . Thus, canine p53 protein functions as a transcription activator and this activity requires the Nterminal domain.
Discussion
The p53 tumour suppressor protein plays a central role in the cellular defence against genotoxic damage. Mutation of the p53 gene has been associated with a large number of human neoplasms (Hainaut et al., 1997) and may contribute to deregulated cell growth and tumour resistance to chemotherapy (Lowe et al., 1994; Wada et al., 1994; Aas et al., 1996) . Recently, mutation of the p53 gene was also shown to occur in a number of dierent cancers of the dog (see Introduction). This suggests that the role of wild type p53 protein in preventing tumour formation and progression may be similar in both humans and dogs.
We show for the ®rst time the isolation of canine p53 cDNA encoding the full length p53 protein.
Expression of the canine p53 protein has allowed a detailed characterization of the overall structure and functional activities of the wild type p53 from the dog. The present results indicate that the primary sequence of wild type canine p53 protein is similar to that of p53 proteins isolated from other species. However, canine p53 does contain a shorter proline-rich region (amino acid residues 61 ± 79) compared to human and murine p53 proteins. The presence of PXXP motifs within the proline-rich region of human p53 (see Figure 2 ) have been suggested to play a role in signal transduction mediated through SH3 domain binding activity (Walker and Levine, 1996) . Recently, the proline-rich region of murine p53 was suggested to participate in transactivation-independent growth arrest (Ruaro et al., 1997) and/or apoptosis (Sakamuro et al., 1997) .
Canine p53 protein is not recognized by the majority of human and murine speci®c anti-p53 antibodies used in this study. This suggests that there may be local dierences in the nature and organization of amino acid residues on the surface of the canine p53 molecule when compared to murine and human p53 proteins. In this respect, it is interesting to note that the primary sequence of the DO1 antibody epitope located in the N-terminus of human p53 (position 20 ± 25) diers by two amino acid residues compared to canine p53 (Glu 21 and Asp 24) and by one amino acid residue when compared with murine p53 (Gly 24). In contrast, strong reactivity of the canine p53 protein towards antibody 421 could be predicted by the presence of the identical C-terminal epitope sequence within canine p53 (position 360 ± 370) and human p53 (position 372 ± 382). The PAb240 epitope which is cryptic in the wild type conformation of the p53 protein (Cho et al., 1994) is also conserved between human and canine p53 proteins. A recent immunohistochemical study of canine cutaneous squamous cell carcinomas suggest that the PAb240 epitope may be exposed in a subset of tumours overexpressing the p53 protein (Teifke and Lohr, Characterization of full length canine p53 N Veldhoen and J Milner 1996) . Whether these PAb240-positive tumours contained mutant p53 genes was not determined.
Canine p53 protein displays speci®c DNA binding activity in vitro similar to both human and murine p53 proteins. All three p53 proteins recognize and form complexes with p53 target sequences derived from the GADD45 and p21 promoters as well as with a consensus p53 binding site. Association of canine p53 protein with the three DNA target oligonucleotides may be explained by the strict conservation of speci®c DNA-binding amino acid residues within the central core domain (Cho et al., 1994) . Such conservation in the recognition of speci®c DNA promoter sequences indicates that the control of downstream genes activated in a p53-dependent manner may also be conserved between species. Binding of speci®c DNA sequences by human p53 also requires the protein to adopt a wild type conformation recognized by the monoclonal antibody 1620 (Hall and Milner, 1995) . The ability of canine p53 protein to associate with speci®c target DNA sequences indicates that it is folded into a wild type conformation. It follows that the lack of reactivity of antibody 1620 with canine p53 may arise from local dierences in amino acid identity within the 1620 epitope of canine p53.
The process of p53 activation in response to genotoxic damage is poorly understood. Recent ®ndings suggest that binding of p53 to sites of DNA damage may induce proteolytic cleavage of the full length protein to generate a speci®c set of`activated' p53 polypeptide fragments (Molinari et al., 1996; Okorokov et al., 1997) . Using an in vitro damaged DNA binding assay we show that canine p53 associates with damaged DNA and can also undergo damaged DNA-dependent proteolytic cleavage. However, the number and size of the polypeptide fragments produced diers between the murine and canine proteins. This dierence in the pattern of proteolytic products may be due to dierences in the number and location of cleavage sites present on the solvent-exposed surface of the canine and murine p53 proteins.
In response to DNA damage, the p53 protein directs a cellular response towards either cell cycle arrest or apoptosis (reviewed in Ko and Prives, 1996; Levine, 1997) . Both responses are cell type-dependent and require p53-associated transactivation of a number of dierent genes. Consistent with this role for p53, our results demonstrate that canine p53 protein can function as an ecient transcription activator in p53 null primary murine embryo ®broblast cells (see Figure 7) . Similar to human p53 protein (Unger et al., 1992 (Unger et al., , 1993 , the transactivation activity of canine p53 protein is localized within the N-terminal domain. Conservation of amino acid residues phenylalanine 19, leucine 22, and tryptophan 23 within the N-terminus of the canine p53 protein may contribute to the transactivation potential of canine p53 protein (Lin et al., 1995) .
In conclusion, the structure, DNA binding and transactivation activities of the canine p53 protein are relatively well-conserved compared with p53 proteins isolated from other species. This indicates that the role of the p53 protein in maintaining genomic DNA integrity may have been established early on in the evolution of higher eukaryotic organisms. Thus, information obtained concerning the role of canine p53 in tumour progression and the ecacy of anticancer therapies directed against p53-associated canine cancers may be directly applicable to the treatment of human cancer.
Materials and methods
Plasmids and bacterial strains
For in vitro analyses, human and murine p53 cDNA were cloned into pBluescript SK + and the resulting plasmids were called ph53 and pm53, respectively. The canine p53 cDNA was cloned into pLitmus 29 and called pK9. The canine p53 mutant cDNA construct cp53DN was cloned into pcDNA3 to create the expression plasmid pc3CDN. Plasmids, pc3M and pc3C contained the murine and canine p53 cDNAs, respectively, cloned into the mammalian expression plasmid pcDNA3. All plasmids were maintained in E. coli XL-1 Blue MRF.
RNA isolation and RT ± PCR ampli®cation
Total RNA was prepared from 10 7 peripheral blood leukocytes isolated from a healthy 1 year old collieretriever cross using the RNeasy RNA isolation kit as per the manufacturers protocol (Qiagen). Complementary DNA fragments containing p53 coding sequence were ampli®ed from 2 mg total RNA using the Access RT ± PCR system as per the manufacturers protocol (Promega). A 5' p53 cDNA fragment was prepared using the primers 5'up and cp53dn while a 3' p53 cDNA fragment was isolated using the primers cp53up and 3'dn. The 5' and 3' cDNA fragments were cloned into pTZRJL1 and pLitmus 29, respectively, and DNA sequencing was performed. From the sequence information obtained, the primers NTup and CTdn were generated and used in RT ± PCR ampli®cation of the complete canine p53 cDNA which was cloned into pLitmus 29 and called pK9.
Construction of canine p53 mutant cp53DN
Mutant canine p53 protein containing a deletion of the Nterminal domain was constructed by cDNA ampli®cation and cloning. The 100 ml ampli®cation reaction contained 10 mM Tris-HCl (pH 8.75 at 208C), 25 mM KCl, 5 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 200 mM dNTPs (dATP, dCTP, dGTP, dTTP), 0.25 mM each of primers DNup and CTdn, 1 ng pK9 and 2.5 units Pwo polymerase (Boehringer). The thermocycle program included a denaturation step at 948C (7 min), 30 cycles of 948C (30 s), 558C (30 s), 728C (1 min) and a ®nal elongation step at 728C (7 min). The ampli®ed DNA product was digested with KpnI and BamHI and cloned into pcDNA3 to create pc3CDN.
Transcription and translation
Plasmids ph53 and pm53 containing human and murine p53 cDNA, respectively, were digested with NotI. Plasmid pK9 containing the canine p53 cDNA was digested with EcoRI. Each 50 ml transcription reaction contained 40 mM Tris-HCl pH 7.5, 6 mM MgCl 2 , 2 mM spermidine, 10 mM dithiothreitol, 20 units RNasin (Promega), 0.5 mM each ATP, CTP and UTP, 0.025 mM GTP, 2 mg template DNA, 0.5 mM m 7 GpppG and 40 units T7 RNA polymerase (Promega). Transcription was allowed to proceed at 378C for 30 min and GTP was added to a ®nal concentration of 1 mM. A further incubation of 60 min at 378C was performed followed by phenol : chloroform extraction, ethanol precipitation, and resuspension in 40 ml of water. The yield and purity of mRNA was estimated by agarose gel electrophoresis.
Human, murine, and canine p53 proteins were translated in a rabbit reticulocyte lysate system as described previously by Gamble and Milner (1988) . A typical translation mix contained 70% (v/v) rabbit reticulocyte lysate (Promega), 2% (v/v) amino acid mix without methionine (Promega) and 10% (v/v) [ 35 S]methionine (40.5 TBq/mmol; Amersham). The translation mix and template mRNA were preincubated for 10 min at 308C and 678C, respectively. Template mRNA was then added to the translation mix at a ®nal concentration of 8% (v/v) and the reaction allowed to proceed for 90 min at 308C and then stored on ice. The eciency of translation was determined by TCA precipitation on glass ®lters followed by scintillation counting.
Immunoprecipitation
Protein conformation was determined by immunoprecipitation with anti-p53 antibodies as described by Cook and Milner (1990) . The following antibodies were used; DO1, PAb1801, PAb242, PAb248, PAb246, PAb1620, PAb240 and PAb421. Antibody PAb416, directed towards the large T-antigen of SV40, was used as a negative control. Immunoprecipitated proteins were resolved by 15% SDSpolyacrylamide gel electrophoresis and visualised by autoradiography with Fuji RX ®lm at room temperature.
DNA binding and proteolytic cleavage
Analysis of p53 DNA binding activity and proteolytic cleavage was performed as described previously by Molinari et al. (1996) . Binding to speci®c DNA sites was assessed using the biotinylated double stranded oligonucleotides CON (Funk et al., 1992) , p21 (oligonucleotides p21up/p21dn) and GADD45 (oligonucleotides GADD45up/GADD45dn). Binding activity to damaged DNA targets was determined by using biotinylated lesion (L-DNA; oligonucleotides Lup and L/NLdn) and non lesion (NL-DNA; oligonucleotides NLup and L/NLdn) double stranded DNA (Lee et al., 1995) and single strand DNA (ssDNA; oligonucleotide L/NLdn). Steptavidinmagnetic beads (15 ml) coated with 30 pmol target DNA oligonucleotides were prepared as described by the manufacturer (Dynal) and then washed twice with 300 ml DNA binding buer containing 20 mM Tris-HCl (pH 7.5 at 208C), 100 mM NaCl, 0.1% NP-40, 6% glycerol and 5 mM DTT. The beads were subsequently incubated in 100 ml DNA binding buer containing 20 ml translated p53 protein for 20 min at 208C. For the speci®c DNA competition experiment (see Figure 4 ) translated p53 protein (20 ml) was preincubated for 10 min with 60 pmol non biotinylated CON DNA in 100 ml DNA binding buer. Biotinylated CON DNA (30 pmol) bound to the streptavidin beads was then added and the reaction incubated for a further 20 min at 208C. Protein ± DNA complexes were washed three times with 400 ml DNA binding buer and resuspended in 30 ml Laemmli's buer (Laemmli, 1970) .
The DNA binding reaction prepared for the analysis of p53 proteolytic cleavage was identical to that described previously. However, following the three washes of protein-DNA complexes with 400 ml DNA binding buer the supernatant was removed and the beads resuspended in 50 ml DNA binding buer and incubated at 378C for 1 h. Protein ± DNA complexes retained on the beads were collected and the supernatant saved for analysis. The beads were washed three times with 400 ml DNA binding buer and resuspended in 30 ml Laemmli's buer. Protein retained on the DNA and released into the supernatant were analysed by 15% SDS ± PAGE.
Transfection assays
The p53 null primary murine embryo ®broblast cell line (18MEFs) was prepared as described by Harvey et al. (1993) . Cells were cultured at 378C in an atmosphere of 5% CO 2 in air in Dulbecco's modi®ed Eagle's (DMEM) media (Gibco) supplemented with 10% foetal calf serum, 2 mM Lglutamine and 100 U/ml penicillin/streptomycin (Gibco). For maintenance the cells were cultured in 25 cm 3 and 75 cm 3¯a sks and passaged 1 in 8 at approximately 70% con¯uency.
Plasmids for transfection were prepared using a midi-prep kit as described by the manufacturer (Qiagen). The reporter plasmid pRGCDfosLacZ, contains the LacZ gene under the control of a p53-inducible promoter (Frebourg et al., 1992) . The expression vectors pc3M and pc3C contain the murine and canine p53 cDNAs under the control of the cytomegalovirus (CMV) promoter. Cells were seeded onto 8 cm dishes at 30% con¯uency, 18 h before transfection. Cotransfections were carried out with Lipofectamine and Opti-MEM as per the manufacturers protocol (Gibco). Ten micrograms of p53 expression plasmid, 10 mg of reporter plasmid, and 50 ml lipofectamine were used per 8 cm dish. The level of b-galactosidase expression was determined 48 h post-transfection using an ONPG assay as described by Rosenthal (1987) .
